MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
Coronavirus Vaccine Stocks$700.66
1.23%4:00PM 03/01/2021
The list of companies include MRNA-Moderna Inc, NVAX-Novavax, Inc., INO-Inovio Pharmaceuticals Inc, IBIO-iBio Inc, PFE-Pfizer Inc., JNJ-Johnson & Johnson, VXRT-Vaxart Inc, OCGN-Ocugen Inc
Latest intraday update before market close @ 20:45:35 PM 03/01/2021
Summary :
Average return is up 1.3%
Median return is up 1.3%
8 out of 10 stocks are up (limited to those with intraday pricing feeds).

Aggregated price index

Aggregated price index with volume information

Summary:

  • Coronavirus Vaccine stocks up 1.2% on average while median return up 1.4% in a day
  • Coronavirus Vaccine stocks down 0.7% on average while median return down 1.7% in a week
  • Coronavirus Vaccine stocks up 45.5% on average while median return up -0.5% in a month
  • When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.

Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.

Related Stocks

Click on + to show price series and click on ticker for stock detail page

Ticker
1 Day Return
1 Week Return
1 Month Return
PE Ratio
PE Growth Ratio
Price to Book (mrq)
Price to Sales (ttm)
Earning Growth
MarketCap
Short %
Held By Institutions %
Price Pattern
Days Since Channel Change
Channel Slope (daily rate %)
Half Channel Bandwidth
Distance to Channel MidPoint %
VXRT5.60%
10.40%
-15.40%
-20.726.36193.45890.3M32.93%38.21%\-1260.08%36.41%-5.05%
INO4.50%
-9.90%
5.90%
-8.935.741076.012.2B21.42%36.49%\-126-0.24%45.95%12.10%
NVAX3.90%
-2.00%
79.30%
-42.45136.7475.9615.3B9.14%50.57%\/-/631.82%15.22%1.19%
IBIO2.80%
-11.70%
13.80%
3.47163.10391M5.71%8.10%/-126-0.35%69.34%28.79%
MRNA1.70%
-1.20%
-1.30%
-96.550.4922.1876.2562.3B4.83%52.06%/630.87%11.17%-6.08%
BNTX1.10%
-3.80%
0.20%
1.4726.5B10.51%/1260.47%11.75%-7.33%
PFE0.60%
-1.70%
-6.10%
19.73.062.854.44187.9B1.14%69.90%\/\63-0.12%6.60%-3.87%
JNJ0.50%
-1.60%
-5.80%
28.913.226.595.04-56.70%418.8B0.58%69.79%\/-/630.20%4.40%-4.69%
SNY0.00%
-1.00%
-3.50%
36.741.791.75115.6B7.04%\/\126-0.07%5.77%-2.39%
OCGN-8.50%
9.20%
421.90%
48310.001.9B7.23%13.13%-/5481.32%14.99%20.20%

* P/E and MarketCap are refreshed daily using IEX Cloud service. P/B, P/S, PEG, growth, short%, HelbyInstitute are refreshed weekly using Yahoo feeds. For latest stock stats please visit Yahoo Finance.

* Price Patter: / is upward trend, \ is downward trend, - is sideway. Click on the ticker to go to stock page to see Bayesian Trend model plot of the time series.

* Channel and change points are derived from Bayesian Trend model, where the channel slope is the growth rate while change points are those the model partition the time series.

Related ETFs (click on ticker for stock detail page)

leak data

  • 1M winners are : Winners for past month are $OCGN 421.9%, $NVAX 79.3%, $IBIO 13.8%, $INO 5.9%, $BNTX 0.2%
  • 1M losers are : Losers for past month are $MRNA -1.3%, $SNY -3.5%, $JNJ -5.8%, $PFE -6.1%, $VXRT -15.4%
  • 1W winners are : Winners for past week are $VXRT 10.4%, $OCGN 9.2%
  • 1W losers are : Losers for past week are $PFE -1.7%, $NVAX -2.0%, $BNTX -3.8%, $INO -9.9%, $IBIO -11.7%
Pick two stocks to compare:

Correlation Analysis

Index correlation analysis

Correlation for the past month is 10.5%, for the past 3 months is 10.2%

In the past month for a 5 days rolling window, the highest corrrelation is 30.1%, the lowest correlation is -2.6%, the latest correlation is 20.7%

When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.

Among pairwise correlation, the highest correlation is 63.6% between BNTX and NVAX

The lowest correlation is -54.8% between JNJ and NVAX

Stock news

    03/1/2021JNJ
    UPDATE 1-Chile to ramp up purchase of Sinovac vaccine, seeking deal with Johnson & Johnson

    Chile plans to ramp up its purchase of vaccines from China's Sinovac and hopes to sign a deal shortly with Johnson & Johnson, the health minister said on Monday, as the South American nation moves to strengthen its widely lauded coronavirus vaccination campaign. Chile has jumped ahead of the rest of Latin America and many countries globally with its inoculation program. The country has already inoculated 3.35 million of its 19 million citizens against COVID-19, officials said on Monday.

    03/1/2021JNJ
    Dow Jones Rips 600 Points Higher, Led By Boeing, Apple; Zoom Video Surges Late On Earnings

    The Dow Jones rallied sharply along with the other major stock indexes Monday, led by strength in Boeing and Apple. Zoom Video surged late on earnings.

    03/1/2021JNJ
    Johnson & Johnson -- Moody's: J&J vaccine emergency authorization is credit positive

    Announcement: Moody's: J&J vaccine emergency authorization is credit positiveGlobal Credit Research - 01 Mar 2021New York, March 01, 2021 -- Moody's Investors Service commented that the US Food & Drug Administration's (FDA) emergency use authorization of Johnson & Johnson's COVID-19 vaccine is credit positive. The company's Aaa rating and negative outlook remain unchanged.For additional information please see Moody's issuer comment on Johnson & Johnson available on www.moodys.com.Please see www...

    03/1/2021NVAX
    Market Recap: Monday, March 1

    U.S. stocks staged a rebound rally on Monday, with each of the S&P 500, Dow and Nasdaq jumping as retreating Treasury yields and vaccine optimism boosted risk assets. Each of the three major indexes increased by more than 2% around noon in New York, and the small-cap Russell 2000 outperformed with a gain of nearly 3%Villere Balanced Fund Portfolio Manager, Lamar Villere, and SVP and Head of Research & Strategy at Global X ETFs, Jay Jacobs, joined Yahoo Finance Live to discuss.

    03/1/2021NVAX
    UPDATE 1-Novavax COVID-19 shot could be cleared for U.S. use by May -CEO

    Novavax Inc's chief executive said on Monday its COVID-19 vaccine could be cleared for use in the United States as soon as May if U.S. regulators authorize it based on data from the company's British trial, which could be completed as soon as April. But he added that talks with the U.S. Food and Drug Administration are ongoing and the FDA may require that Novavax submit data from its U.S. trial, which could take an additional two months to read out and push back U.S. clearance to mid-summer. N...

    03/1/2021INO
    UPDATE 1-Inovio completes enrolment in mid-stage U.S. study of COVID-19 vaccine

    U.S. vaccine developer Inovio Pharmaceuticals Inc said on Monday it had completed Phase II enrolment for a mid-to-late stage U.S. trial of its COVID-19 vaccine candidate. Inovio began developing the vaccine last year, but is running behind rivals who have already introduced their candidates in the United States. The delay occurred as the U.S. Food & Drug Administration in September put on hold the Phase III portion of the U.S. study of Inovio's vaccine candidate, INO-4800, as it sought more in...

    03/1/2021NVAX
    Novavax higher after posting quarterly earnings

    Novavax reported mixed quarterly earnings, posting a beat on the top line but not on the bottom line. The pharmaceutical company reported $279.7M in revenue and a loss per share $2.70, compared to Street estimates of in $202.6M revenue and a loss per share of $2.24. Yahoo Finance's Jared Blikre joined Yahoo Finance Live to break down the details.

    03/1/2021NVAX
    Novavax posts wider quarterly loss, sales jump due to pandemic-related services

    Shares of Novavax Inc. wavered between gains and losses in the extended session Monday after the biotech company reported a wider-than-expected fourth-quarter loss but its sales beat Wall Street expectations. Novavax said it lost $177.6 million, or $2.70 a share, in the quarter, compared with a net loss of $31.8 million, or $1.13 a share, for the fourth quarter of 2019. Revenue rose to $279.7 million, from $8.8 million a year ago. The revenue jump was thanks to services rendered in connection wi...

    03/1/2021BNTX
    JNJ Stock Rises In Buy Zone As U.S. Begins Distributing Third Covid Vaccine

    Distribution began Monday for Johnson & Johnson's newly authorized one-shot coronavirus vaccine, leading JNJ stock to pop in early action. McKesson is distributing the J&J vaccine.

    03/1/2021JNJ
    US STOCKS-S&P 500 surges in strongest one-day rise since June

    The S&P 500 surged on Monday in its strongest one-day gain since June as bond markets calmed after a month-long selloff, while another COVID-19 vaccine getting U.S. approval and fiscal stimulus bolstered expectations of a swift economic recovery. Johnson & Johnson ended up 0.5%, but off earlier highs, after it began shipping its single-dose vaccine after it became the third authorized COVID-19 vaccine in the United States over the weekend. U.S. bond yields eased after a swift rise last month o...